Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′ CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.
1. A compound having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof.
2. The compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof according to claim 1 , wherein the compound is the sodium, potassium, calcium, magnesium, zinc, aluminum, ammonium, diethylamine, olamine, benzathine, benethamine, tromethamine (2-amino-2-(hydroxymethyl)propane-1,3-diol), morpholine, epolamine, piperidine, picoline, dicyclohexylamine, N,N′-dibenzylethylenediamine, 2-hydroxyethylamine, tri-(2-hydroxyethyl)amine, chloroprocaine, choline, deanol, imidazole, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine, dibenzylpiperidine, dehydroabietylamine, glucamine, collidine, quinine, quinolone, erbumine, lysine or arginine salt thereof.
3. The compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof according to claim 1 , wherein the compound is the sodium salt thereof.
4. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof according to claim 1 and a pharmaceutically acceptable excipient.
5. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof according to claim 1 , another therapeutic agent and a pharmaceutically acceptable excipient.
6. A method for treating an individual suffering from cancer, comprising:
non-parenterally or parenterally administering to the individual an effective amount of the compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof according to claim 1 .
7. The method according to claim 6 , wherein the method further comprises administering one or more additional cancer therapies to the individual, wherein the one or more additional cancer therapies is selected from the group consisting of radiation therapy, surgery, a chemotherapy, or an immunotherapy.
8. A method of treating a disease in an individual, comprising: administering to the individual in need thereof i) an effective amount of the compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof according to claim 1 ; and ii) an effective amount of one or more therapeutic antibodies that induce antibody-dependent cellular cytotoxicity, wherein the disease is selected from the group consisting of a cancer, acute rejection of an organ transplant, Type I diabetes mellitus, rheumatoid arthritis, psoriasis, Crohn's disease, restenosis and allergic asthma.
9. A method according to claim 7 , wherein the one or more additional cancer therapies comprise administering a checkpoint inhibitor.
10. A method according to claim 9 , wherein the immune checkpoint inhibitor is selected from the group consisting of a CTLA-4 pathway antagonist, a PD-1 pathway antagonist, a Tim-3 pathway antagonist, a Vista pathway antagonist, a BTLA pathway antagonist, a LAG-3 pathway antagonist, and a TIGIT pathway antagonist.